135898-05-4

Basic information

• Product Name: 3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2-methyl-2-<6-<(4-methylphenyl)sulfonyl>4,8,12-trimethyltrideca-3(E),7(E),11-trienyl>-2H-1-benzopyran
• CAS NO: 135898-05-4
• Molecular Weight: 624.882
• Mol File: 135898-05-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2-methyl-2-<6-<(4-methylphenyl)sulfonyl>4,8,12-trimethyltrideca-3(E),7(E),11-trienyl>-2H-1-benzopyran(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2-methyl-2-<6-<(4-methylphenyl)sulfonyl>4,8,12-trimethyltrideca-3(E),7(E),11-trienyl>-2H-1-benzopyran(135898-05-4)
• EPA Substance Registry System: 3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2-methyl-2-<6-<(4-methylphenyl)sulfonyl>4,8,12-trimethyltrideca-3(E),7(E),11-trienyl>-2H-1-benzopyran(135898-05-4)

Safety Data

• Hazardous Substances Data: 135898-05-4(Hazardous Substances Data)

Upstream product

• 53254-60-7 3,7-dimethyl-1-(p-toluenesulfonyl)-2(E),6-octadiene 
• 135898-04-3 3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2-methyl-2-(5-chloro-4-methyl-3(E)-pentene)-2H-1-benzopyran 
• 135897-93-7 ethyl 5-<3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2,7,8-trimethyl-2H-1-benzopyran-2-yl>-2-methyl-2(E)-pentenoate 
• 135897-96-0 5-<3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2,7,8-trimethyl-2H-1-benzopyran-2-yl>-2-methyl-2(E)-penten-1-ol 
• 143172-86-5 (2E,6E)-8-(2,5-Dihydroxy-3,4-dimethyl-phenyl)-2,6-dimethyl-octa-2,6-dienoic acid ethyl ester 
• 135897-95-9 (E)-5-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-2-methyl-pent-2-enoic acid ethyl ester 
• 135897-91-5 ethyl 2,6-dimethyl-8-<(tetrahydro-2H-pyran-2-yl)oxy>-2(E),6(E)-octadienoate 
• 135897-92-6 ethyl (2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dienoate 
• 64218-01-5 (E)-6-hydroxy-4-methyl-4-hexenal tetrahydropyranyl ether 

Relevant articles and documents

Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders

This invention relates to the use of tocotrienol, gamma-tocotrienol and delta-tocotrienol in reducing hypercholesterolemia, hyperlipidemia and thromboembolic disorders in mammals. [The isolation of these tocotrienols from natural sources and their chemical synthesis is disclosed.] The chemical synthesis of these tocotrienols is disclosed. The present invention also relates to prodrugs and pharmaceutical compositions of gamma-tocotrienol, delta-tocotrienol and tocotrienol and uses thereof.